



MAYNE PHARMA ANNOUNCED AS RECIPIENT OF \$4.8M FEDERAL GOVERNMENT GRANT

9 May 2022, Adelaide Australia: Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that its application for a Federal Government Modern Manufacturing Initiative (MMI) Grant has been successful. The maximum grant funding is A\$4.8 million and is conditional on Mayne Pharma and the Commonwealth entering into a funding agreement.

Mayne Pharma's Salisbury facility is the largest Australian owned full service solid oral dose and topical plant manufacturing TGA and FDA registered pharmaceuticals in Australia. The site offers full 'end to end' pharmaceutical services from development through to commercial manufacturing and distribution. Mayne Pharma has over 40-years of Good Manufacturing Practice (GMP) certification from the TGA and FDA including developing and manufacturing a number of WHO-recognised essential medicines.

Mayne Pharma's CEO Mr Scott Richards said, "This grant will allow Mayne Pharma to expand its advanced manufacturing capability and capacity and ensure the Salisbury site remains one of Australia's leading solid oral dose manufacturing facilities. The project seeks to more than double the encapsulation and blister packaging capacity and introduce new technologies such as serialisation to support the export of select solid oral dose products."

For further information contact:

Lisa Pendlebury (VP Investor Relations & Communications)
+61 419 548 434, lisa.pendlebury@maynepharma.com

Authorised for release to the ASX by the Chair

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel and generic pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma also provides contract development and manufacturing services to clients worldwide.

Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world.

Mayne Pharma has two facilities based in Salisbury, Australia and Greenville, NC, US with expertise in the formulation of complex oral and topical dose forms including potent compounds, modified-release products and poorly soluble compounds.

Mayne Pharma Group Limited

ABN 76 115 832 963

maynepharma.com

1538 Main North Road, Salisbury South, SA 5106 Australia